This site is intended only for healthcare professionals resident in the Republic of Ireland
400 mg BOSULIF once daily for adult patients with newly diagnosed chronic phase (CP) Philadelphia chromosome–positive chronic myelogenous leukemia (Ph+ CML)
Dose escalation or reduction by 100mg may be considered depending on patients response and tolerability. Doses greater than 600 mg/day have not been studied and, therefore, should not be given. Doses less than 300 mg/day have been used in patients; however, efficacy has not been established.
Take a look at the other resources to support you
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023